It appears as if it's Ebola Time.
As the video below proves, the Spanish military charged with transporting dead victims of the Ebola virus from Africa back home to Spain either:
1) Woefully and with supreme foolishness failed to take proper precautions against the spread of the virus both within the aircraft used and again once it was time to unload the cargo, or
2) Intentionally ignored protocols for the express purpose of allowing the virus to spread into Europe.
Watch it and see what you think:
The Center for Disease Control has this to say:
When cases of the disease (Ebola) do appear, there is increased risk of transmission within health care settings. Therefore, health care workers must be able to recognize a case of Ebola HF and be ready to employ practical viral hemorrhagic fever isolation precautions or barrier nursing techniques. They should also have the capability to request diagnostic tests or prepare samples for shipping and testing elsewhere.
wearing of protective clothing (such as masks, gloves, gowns, and goggles)Barrier nursing techniques include:
- the use of infection-control measures (such as complete equipment sterilization and routine use of disinfectant)
- isolation of Ebola HF patients from contact with unprotected persons.
The aim of all of these techniques is to avoid contact with the blood or secretions of an infected patient. If a patient with Ebola HF dies, it is equally important that direct contact with the body of the deceased patient be prevented.
Why do some believe this strain of Ebola is in fact a weaponized version? This Ebola outbreak does not follow the pattern set by every previous outbreak. "In the past, 'there's been a spike and then it drops off,' to zero, microbiologist Tom Geisbert says. But for some reason that has health officials mystified, this particular outbreak didn't follow the pattern.
It looked like it was going to, mind you, at least until late May."
On May 18 the WHO stated this current outbreak could be over by May 22. "But then the number of new cases again began to move higher, and in July spiked sharply upwards. By early July, WHO was already saying the outbreak was out of control.
"And it was Liberia that has had the most new cases, according to the latest WHO update. In the seven days ended Aug. 6, there were 339 new cases (confirmed, probable or suspect), 163 of them in Liberia. There have now been at least 1,779 cases and 961 deaths from Ebola in West Africa.
"On Thursday, Liberia declared a state of emergency to fight the virus. Fewer than 24 hours later, WHO declared the outbreak is a "public health emergency of international concern" at a press conference held in Geneva, Switzerland."
Microbiologist Tom Geisbert says: "This outbreak has been very different compared to any Ebola outbreak in the past, and so we don't really have much historical perspective."
Tom Geisbert, a top expert on Ebola, says, 'This outbreak has been very different compared to any Ebola outbreak in the past.' (Univ. of Texas Medical Branch)
Geisbert, who researches Ebola at the University of Texas Medical Branch in Galveston, says that what sets this outbreak apart from previous ones, and makes it "incredibly hard to control" is that this time around, it has taken hold over a large geographical area and three countries.
Therapies and Vaccines
Further, until quite recently Ebola was considered to be untreatable. But suddenly there are a number of therapies and vaccines in the pharma pipeline:
"Mapp Biopharmaceutical’s ZMapp experimental treatment is a combination or cocktail of three monoclonal antibodies that is designed to bind to the protein of the Ebola virus, neutralizing the virus so it can’t do any further damage.
ZMapp was given to two American health workers infected with Ebola in Liberia.
The last of the drug is on its way to Liberia for two stricken doctors, according to a U.K.-based public relations firm representing Liberia.
The drug resulted from a collaboration between Mapp Biopharmaceutical, LeafBio, Defyrus, the U.S. government and the Public Health Agency of Canada. It is grown in tobacco plants.
The CDC’s website says two other companies, B.C.-based Tekmira and Biocyst Pharmaceuticals, have received funding from the U.S. Department of Defence. Both companies also have therapeutic candidates for Ebola.
Tekmira’s experimental drug, TKM-Ebola, targets Ebola's genetic material. The U.S. Food and Drug Administration halted a small safety study with questions about a reaction in healthy volunteers, but last week Tekmira announced that the FDA had modified its restriction. The FDA change means the experimental drug, known as an RNA interference therapeutic, could potentially be used on people infected with Ebola, the company said.
One experimental Ebola vaccine was also partly developed at Canada’s National Microbiology Lab.Canada is in discussions with other countries and the World Health Organization about sending doses of the vaccine to West Africa, a spokesman for Health Canada says.
Another experimental vaccine developed at the U.S. National Institute of Allergy and Infectious Diseases and licensed by GlaxoSmithKline is expected to begin first-stage safety studies sometime in the fall.
Another experimental vaccine from Johnson & Johnson's Crucell unit should enter phase 1 clinical trials in
late 2015 or early 2016. Profectus Biosciences is also working with U.S. scientists on another preclinical vaccine."
No comments:
Post a Comment